Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Custirsen sodium: Phase III amended

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: Custirsen sodium (TV-1011, OGX-011) Business: Cancer Molecular target: Clusterin mRNA …

    Published on 7/20/2015
  • Custirsen sodium: Phase III ongoing

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Product: Custirsen sodium (TV-1011, OGX-011) Business: Cancer Molecular target: Clusterin mRNA …

    Published on 7/20/2015
  • EGP-437: Phase Ib/IIa started

    EyeGate Pharmaceuticals Inc. (OTCQB:EYEG), Waltham, Mass. Product: EGP-437 Business: Ophthalmic Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered by the EyeGate II Drug Delivery …

    Published on 7/20/2015
  • ETC-159: Phase I started

    Agency for Science, Technology and Research, Singapore Product: ETC-159 Business: Cancer Molecular target: NA Description: Inhibitor of the Wnt cell signaling pathway Indication: Treat advanced solid tumors Endpoint: …

    Published on 7/20/2015
  • FR104: Phase I started

    Effimune S.A.S., Nantes, France Product: FR104 Business: Autoimmune Molecular target: CD28 receptor Description: Pegylated monovalent antibody fragment antagonist of CD28 receptor Indication: Treat immune-mediated …

    Published on 7/20/2015
  • Galeterone: Phase III started

    Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Product: Galeterone (TOK-001) Business: Cancer Molecular target: Androgen receptor; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A) …

    Published on 7/20/2015
  • Horizant gabapentin enacarbil: Phase II started

    XenoPort Inc. (NASDAQ:XNPT), Santa Clara, Calif. Product: Horizant gabapentin enacarbil (Regnite) (GSK1838262, XP13512) Business: Neurology Molecular target: Calcium channel N-type Description: Transported prodrug of …

    Published on 7/20/2015
  • HP-3150: Phase II/III started

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: HP-3150 Business: Neurology Molecular target: NA Description: Transdermal patch containing NSAIDs Indication: Treat cancer pain Endpoint: NA Status: …

    Published on 7/20/2015
  • IV solithromycin: Completed Phase III enrollment

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Toyama Chemical Co. Ltd., Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: IV solithromycin (CEM-101) (formerly OPT-1068) Business: Infectious Molecular …

    Published on 7/20/2015
  • Lagova: Completed Phase III enrollment

    Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK), Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova, hGH-CTP (PF-06836922, MOD-4023) Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting …

    Published on 7/20/2015
  • NBTXR3: Phase I/II start

    Nanobiotix S.A. (Euronext:NANO), Paris, France PharmaEngine Inc. (GreTai:4162), Taipei, Taiwan Product: NBTXR3, PEP503 Business: Cancer Molecular target: DNA Description: Crystalline nanoparticles of hafnium oxide …

    Published on 7/20/2015
  • Omadacycline: Phase III started

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Product: Omadacycline (formerly PTK 0796) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Aminomethylcycline antibiotic Indication: …

    Published on 7/20/2015
  • Oral BAL101553: Phase I/IIa started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: Oral BAL101553 Business: Cancer Molecular target: Tubulin Description: Water-soluble prodrug of BAL27862, an apoptosis-inducing small molecule targeting …

    Published on 7/20/2015
  • oral RTA 408: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas Product: oral RTA 408 Business: Endocrine/Metabolic Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); Nuclear factor of kappa light polypeptide gene…

    Published on 7/20/2015
  • Oramed Insulin Capsule: Phase IIb started

    Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), Jerusalem, Israel Product: Oramed Insulin Capsule (ORMD-0801) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Oral capsule formulation of …

    Published on 7/20/2015
  • Rivipansel: Phase III started

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 7/20/2015
  • SYN-010: Phase II started

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-010 Business: Gastrointestinal Molecular target: HMG-CoA reductase Description: Oral modified-release formulation of lovastatin, an HMG-CoA reductase …

    Published on 7/20/2015
  • Tirasemtiv: Phase III start

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Tirasemtiv (formerly CK-2017357) Business: Neurology Molecular target: Sarcomere Description: Fast skeletal muscle troponin activator Indication: …

    Published on 7/20/2015
  • TransVax: Completed Phase II enrollment

    Vical Inc. (NASDAQ:VICL), San Diego, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: TransVax, Cytomegalovirus (CMV) vaccine (VCL-CB01, ASP0113) Business: Infectious Molecular target: Human …

    Published on 7/20/2015
  • VX15/2503: Phase II started

    Vaccinex Inc., Rochester, N.Y. Product: VX15/2503 Business: Neurology Molecular target: Semaphorin 4D (SEMA4D) Description: Humanized mAb against semaphorin 4D (SEMA4D) Indication: Treat Huntingtons disease (HD) …

    Published on 7/20/2015
  • Woxheal: Phase II/III ongoing

    Centaur Pharmaceuticals Pvt. Ltd., Mumbai, India CytoTools AG (Xetra:T5O), Darmstadt, Germany Product: Woxheal (DermaPro) (CLO5) Business: Dermatology Molecular target: NA Description: Derivative of dichloric acid …

    Published on 7/20/2015
  • AAV2-REP1: Phase II started

    NightstaRx Ltd., London, U.K. Product: AAV2-REP1 Business: Ophthalmic Molecular target: Rab escort protein 1 (CHM) (REP1) Description: Adeno-associated viral (AAV) serotype 2 vector carrying the wild-type copy of the …

    Published on 7/13/2015
  • Adipose-derived regenerative cells: Completed Phase IIb enrollment

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived regenerative cells (ADRCs) (Cytori Cell Therapy, ECCO-50) Business: Autoimmune Molecular target: Not available Description: …

    Published on 7/13/2015
  • AG-348: Phase II started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-348 Business: Endocrine/Metabolic Molecular target: Pyruvate kinase R Description: Oral small molecule activator of pyruvate kinase R Indication: …

    Published on 7/13/2015
  • AGT-182: Phase I started

    ArmaGen Inc., Calabasas, Calif. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: AGT-182 Business: Endocrine/Metabolic Molecular target: NA Description: Iduronate-2-sulfatase (IDS) using Trojan horse …

    Published on 7/13/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993